Reviewed clinical summary · Source-linked · Educational use only

How do ‘FenuflakesTM’ affect 24-hour glycemic variability in adults with type 2 diabetes?

Clinical Bottom Line

A small CGM crossover study finds 30 g/day defatted fenugreek flakes reduces 24-hour glucose excursions and variability in type 2 diabetes. PICO summary and commentary.

Summary: In a small randomised crossover study using continuous glucose monitoring, adding 30 g of defatted fenugreek seed flakes to the diet for 14 days reduced 24-hour glucose excursions and variability in Asian Indian adults with type 2 diabetes.

PICO Summary

ElementDetail
Population21 enrolled, 15 completed, Asian Indian adults (42–50 years) with type 2 diabetes; randomised crossover CGM study, India.
InterventionIso-caloric diet with 30 g/day defatted fenugreek seed flakes (Fenuflakes) for 14 days.
ComparisonMatched iso-caloric control diet without Fenuflakes (crossover).
OutcomeThe test diet reduced 24-hour incremental area under the glucose curve (p=0.02) and mean amplitude of glycaemic excursions (p=0.006) versus control. Within the test diet, fasting glucose and HbA1c fell over 14 days (p<0.05). No major adverse effects.
RCT Asia Pac J Clin Nutr · 2025

Fenuflakes and glycaemic variability

Crossover RCT · type 2 diabetes · 14 days

Trial design
T2D adults, India (n=15) Enrolled & assessed RANDOMISED crossover Test diet Diet + 30 g Fenuflakes n = 15 Control diet Iso-caloric diet n = 15 24-h glucose iAUC & MAGE (CGM)
Change from baseline — both arms
glycaemic variability (MAGE) Baseline Day 14 MAGE reduced, p=0.006 Test diet Control diet
24-h iAUC
Reduced
p=0.02 vs control
MAGE
Reduced
p=0.006 vs control
Fasting glucose
Fell
within test, p<0.05
HbA1c
Fell
within test, p<0.05
⬡ Bottom Line

Over 14 days, adding 30 g/day defatted fenugreek flakes to the diet significantly lowered 24-hour glucose excursions and variability versus a matched iso-caloric control diet. A small, short, manufacturer-affiliated crossover trial, so a plausible dietary adjunct rather than proven therapy.

Expert Commentary

This is a methodologically tidy small study whose crossover design and continuous glucose monitoring give it more internal credibility than its modest size might suggest, since each participant served as their own control and the outcome was measured objectively rather than by self-report. The signal is coherent and biologically plausible: fenugreek is rich in soluble fibre and galactomannan that slow gastric emptying and carbohydrate absorption, so a reduction in both 24-hour glucose excursion and amplitude of variability fits the mechanism, and reduced glycaemic variability is itself increasingly viewed as relevant to complications beyond mean glucose. My reservations are about magnitude and durability rather than direction. Only 15 of 21 participants completed, the intervention lasted just 14 days, the within-diet HbA1c change over two weeks should be read cautiously since HbA1c reflects months of glycaemia, and the study was conducted by a group affiliated with the product’s manufacturer. Can I use this with my patients? Yes, as sensible dietary advice rather than a proven therapy. For a patient interested in food-based approaches, incorporating fenugreek is low-risk and plausibly smooths post-meal spikes, while I would frame it as an adjunct to proven glucose-lowering treatment rather than a substitute, and await longer independent trials.

References

Deshpande PO, Gokhale CA, Bhaskaran S, et al. Effect of ‘Fenuflakes’ on 24-hour glycemic variability in adults with type 2 diabetes: a randomized crossover continuous glucose monitoring study. Asia Pac J Clin Nutr. 2025;34(5):730–739. doi:10.6133/apjcn.202510_34(5).0003

Educational use: Hormone Insight is intended for healthcare professionals and learners. Interpret each summary alongside the primary source, local guidance, and patient-specific clinical judgement.

Subscribe now

Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.

© 2024-2026 Hormone Insight. All rights reserved.